Trial Profile
BR55 Contrast Enhanced Ultrasound (CEUS) in Characterization of Ovarian Lesions
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Aug 2023
Price :
$35
*
At a glance
- Drugs BR-55 (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions; Diagnostic use
- Sponsors Bracco Diagnostics
- 31 Jul 2023 Planned End Date changed from 1 Jan 2022 to 31 Dec 2023.
- 31 Jul 2023 Status changed from completed to active, no longer recruiting.
- 28 Feb 2022 Status changed from recruiting to completed.